Dante Vargas Vásquez

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

Gustavo E. Velásquez, Meredith B. Brooks, Julia Coit et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 113 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Simon Tiberi, Marie-Christine Payen, Giovanni Sotgiu et al. · European Respiratory Journal · 2016 · 100 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Comparison of effectiveness and safety of imipenem/clavulanate-<i>versus</i>meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Simon Tiberi, Giovanni Sotgiu, Lia D’Ambrosio et al. · European Respiratory Journal · 2016 · 81 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis

Charles A. Peloquin, Gustavo E. Velásquez, Leonid Lecca et al. · Antimicrobial Agents and Chemotherapy · 2017 · 43 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · The Lancet Respiratory Medicine · 2025 · 24 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14